Caribou Biosciences (CRBU) Operating Leases (2022 - 2026)

Caribou Biosciences (CRBU) has 5 years of Operating Leases data on file, last reported at $25.7 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 5.49% year-over-year to $25.7 million in Q1 2026; TTM through Mar 2026 was $25.7 million, a 5.49% increase from a year earlier, with the FY2025 full-year figure at $26.0 million, up 3.85% from the prior year.
• Operating Leases for Q1 2026 stood at $25.7 million, down from $26.0 million in the prior quarter.
• Over the last five years, Operating Leases for CRBU reached as high as $27.5 million in Q3 2023 and fell as low as $22.8 million in Q3 2025.
• Historically, Operating Leases has averaged $26.0 million across 5 years, with a median of $26.2 million in 2023.
• Across the five-year window, Operating Leases slipped 14.5% in 2025 and rose 5.49% in 2026, its largest moves.
• Year by year, Operating Leases stood at $26.8 million in 2022, then retreated by 3.26% to $25.9 million in 2023, then retreated by 3.27% to $25.1 million in 2024, then climbed by 3.85% to $26.0 million in 2025, then fell by 1.41% to $25.7 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $25.7 million in Q1 2026, $26.0 million in Q4 2025, and $22.8 million in Q3 2025.